NEXIUM

Compare NEXIUM  to:
Compare
Compare

Generic Name for NEXIUM

Esomeprazole (as magnesium trihydrate) 20mg, 40mg; caps containing e-c delayed-release pellets.

Legal Classification:

Rx

Pharmacological Class for NEXIUM

Proton pump inhibitor.

Manufacturer of NEXIUM

AstraZeneca Pharmaceuticals

Indications for NEXIUM

Triple therapy (w. amoxicillin + clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment and maintenance of healing of erosive esophagitis (EE), symptomatic GERD. To reduce risk of NSAID-associated gastric ulcer. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult dose for NEXIUM

Take 1 hour before food. Caps: swallow whole or may open caps and sprinkle pellets on 1 tablespoon applesauce and take immediately. May open caps and mix granules in 50mL of water and give via NG tube; flush tube with more water. Susp: mix contents of packet in 15mL of water, leave 2–3 minutes, then drink within 30 minutes. May give via NG or gastric tube (see literature). Triple therapy: esomeprazole 40mg once daily + amoxicillin 1g twice daily + clarithromycin 500mg twice daily; all for 10 days. EE: 20 or 40mg once daily for 4–8 weeks, may continue 4–8 more weeks. Maintenance of healing of EE: 20mg once daily. Symptomatic GERD: 20mg once daily for 4 weeks, may continue 4 more weeks. NSAID-associated ulcer risk reduction: 20mg or 40mg once daily for up to 6 months. Hypersecretory conditions: initially 40mg twice daily, adjust if needed; doses up to 240mg daily have been used. Severe hepatic impairment: max 20mg/day.

Children's dosing for NEXIUM

<1yr: not recommended. GERD: 1–11yrs: <20kg: 10mg; ≥20kg: 10 or 20mg; 12–17yrs: 20 or 40mg. For all: give once daily for up to 8 weeks.

Also:

Warnings/Precautions for NEXIUM

Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for NEXIUM

Concomitant atazanavir, nelfinavir: not recommended. May potentiate saquinavir; monitor and consider reducing saquinavir dose. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron salts, digoxin). May affect drugs metabolized by CYP2C19. Monitor warfarin. May give antacids concomitantly.

Adverse Reactions for NEXIUM

Headache, diarrhea, abdominal pain, nausea, flatulence, constipation, dry mouth, inj site reactions; rare: rash, allergic reactions.

Notes for NEXIUM

See Biaxin for more information on clarithromycin. See Amoxil for more information on amoxicillin.

How is NEXIUM supplied?

Caps—30, 90, 1000
Susp—30 packets/box
IV soln (single-use vial)—10

Related Disease:

Duodenal ulcers {DU}
Erosive esophagitis
GERD {GERD}
Hypersecretory conditions~Zollinger-Ellison syndrome
Ulcers, duodenal
Ulcers, gastric

Related Resources

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions